Article Text

Download PDFPDF

Extensive tendon and tuberous xanthomas in a patient with familial hypercholesterolaemia
  1. Ayan Roy,
  2. Sadishkumar Kamalanathan,
  3. Dukhabandhu Naik and
  4. Jaya Prakash Sahoo
  1. Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
  1. Correspondence to Dr Jaya Prakash Sahoo; jppgi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


A 37-year-old man came to endocrinology out patient department with erectile dysfunction for 2 years. His libido was normal and he had no history of decrease in shaving frequency or loss of axillary and pubic hair. He did not have diabetes or hypertension. However, he had an episode of acute severe chest pain in May 2018, when he was diagnosed with an abdominal aortic aneurysm. He underwent aortic stenting in June 2018. Subsequently, he developed a leak in the graft, and glue repair was performed in August 2018. During the evaluation, he was found to have several swellings in the bilateral knee region and one of the swellings was excised during aneurysm repair. The histopathology report showed nodules with numerous cholesterol deposits in the centre surrounded by mild lymphohistiocytic infiltrates and separated by fibrous bands; suggestive of tuberous xanthoma. He was put on aspirin 150 mg, atorvastatin 40 mg and clopidogrel 75 mg as a secondary prophylaxis and was referred to the endocrinology department for metabolic workup.

On further inquiry, he revealed that he is having multiple swellings around the elbow, hip, knee, and ankle areas since childhood. He also confirmed that his elder sister has similar swellings. Nevertheless, his father died at the age of 30 years but the exact cause of death is not known. But, he denied any other family history of premature atherosclerotic cardiovascular disease or premature death related to cardiac disease. His physical examination revealed a body mass index of 21.1 kg/m2 and normal blood pressure. He had bilateral incomplete corneal arcus involving mainly the superior and inferior limbus of the cornea (figure 1A). He had extensive multiple large, globular, non-tender, soft to firm swellings around the knee, ankle, elbow and small joints of the feet (figure 1B–D). He had thickening and widening of the Achilles tendons in both the legs (figure 1D,E).

Figure 1

Clinical photograph of the patient showing corneal arcus (A), Xanthomas around Elbow (B), Knee(C) and Foot(D) . There is also severe thickening of the Achiles tendon clinically(E) and radiologically (F) .

Standing lateral X-ray of the right foot showed a width of the Achilles tendon as 3.12 cm (<9 mm is normal1) (figure 1F). On the other hand, he had normal secondary sexual characters with a bilateral testicular volume of 20 ml.

His lipid profile was as follows: total cholesterol: 469 mg/dL; low-density lipoprotein (LDL): 353 mg/dL; triglyceride (TG):103 mg/dL; very LDL (VLDL):24 mg/dL and high-density lipoprotein (HDL):44 mg/dL. His thyroid function was normal and morning (8 AM) serum testosterone was 600 ng/dL, ruling out underlying hypogonadism. We screened her 63-year-old mother who was asymptomatic. She had no xanthoma on physical examination. But, her lipid profile was suggestive of severe hypercholesterolaemia: total cholesterol: 513 mg/dL; LDL: 335 mg/dL; TG: 190 mg/dL; VLDL: 44 mg/dL and HDL: 60 mg/dL. The index patient was diagnosed with familial hypercholesterolaemia (FH) (possibly homozygous) and was started on atorvastatin 80 mg along with ezetimibe 20 mg daily. His erectile dysfunction was attributed to possible vascular aetiology.

Tendon with or without tuberous xanthomas are usually considered as a pathognomonic clinical sign of homozygous FH. Nevertheless, many differentials should be considered before establishing the diagnosis.Tendon xanthomas can also be seen in patients with heterozygous FH (HeFH).2 However, they are not evident at the time of HeFH diagnosis nowadays, because of widely prescribed lipid-lowering therapy. Extensive xanthomas are rarely seen nowadays. Importantly, xanthomas are often missed and consequently, treatments are delayed.3 Other differentials for this patient are autosomal recessive hypercholesterolaemia, cerebrotendinous xanthomatosis and sitosterolaemia. However, the absence of neurological involvement excludes the possibility of cerebrotendinous xanthomatosis. Sitosterolaemia is an autosomal recessive disorder characterised by the accumulation of plant sterols and is often associated with haematological manifestations like haemolytic anaemia, stomatocytes and macrothrombocytopenia. The absence of such abnormalities and a dominant inheritance pattern makes the diagnosis of sitosterolaemia unlikely in this patient. Finally, a genetic analysis would have been helpful to characterise the defect exactly.

Heterozygous and homozygous FH have a prevalence of one in 250–500 and one in 1 million respectively worldwide.4 Tendon and tuberous xanthomas serve as an important clinical clue to the diagnosis of FH aiding in early treatment. Nevertheless, the commonly prescribed statins are not very effective in homozygous FH. Currently, LDL apheresis along with innovative therapies such as PCSK9 inhibitors or Lomitapide are a part of the standard care.

Learning points

  • Tendon with or without tuberous xanthomas are a pathognomonic clinical sign of familial hypercholesterolaemia (FH), which is often missed.

  • FH should be considered in a patient with premature cardiovascular disease without traditional risk factors.

  • Early diagnosis of FH can facilitate the management of this common disorder and help prevent future cardiovascular events in family members.

  • Autosomal recessive hypercholesterolaemia, cerebrotendinous xanthomatosis and sitosterolaemia are other differentials of tendon xanthomas presenting with elevated low-density lipoprotein cholesterol levels.



  • Contributors AR acquired the clinical data and drafted the manuscript. SK, JPS and DN supervised the work and revised the manuscript with intellectual input.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.